; AbbVie Inc has risen higher in 5 of those 8 years over the subsequent 52 week period, corresponding to a historical probability of 62 % ; Is AbbVie Inc Stock Undervalued? 04:17 PM ET What's particularly impressive is that the annual growth rate of Abbott's medical device business has consistently hovered near the 10% mark, thanks to some of Abbott's recent acquisitions. But can AbbVie build momentum for growth, given that its best-selling products face a number of new competitors? This segment accounted for 14% of Abbott's 2018 revenues. @themotleyfool #stocks $ABBV $PFE $MS $GILD $ABT, it purchased for cash and stock in 2019 for $63 billion, 3 Stocks to Buy With Dividends Yielding More Than 4%, Coronavirus Stimulus Checks: Top Stocks To Buy Now, 2 High-Yielding Dividend Stocks to Buy if the Market Crashes Again, Copyright, Trademark and Patent Information. Since its 2013 separation from Abbott Laboratories (NYSE:ABT), AbbVie's stock has grown more than 160%. Global Cisatracurium Besylate Injection Market Growth 2020-2025. AbbVie (ABBV) closed at $104.70 in the latest trading session, marking a +1.21% move from the prior day. Start a 14-day free trial to Morningstar Premium to unlock our price to fair value estimate. This division accounted for 37% of the company's 2018 revenue, approximately $11.4 billion in total. To get an idea of where Abbott will be in five years, let's look into what's fueled its impressive growth over the past few years and what's going on now. It wouldn't be surprising if revenues from this business segment cracks $7 billion annually. The most notable one was the $25 billion St. Jude Medical acquisition in 2016, another medical device maker that created devices in the cardiovascular and diabetes markets. AbbVie raised the lower end of its 2020 adjusted profit per share forecast by 12 cents to $10.47 and the top range by 4 cents to $10.49. AbbVie, Inc. Stock Forecast, "ABBV" Stock Predictons by days: 2025 Get Our PREMIUM … AbbVie reported total sales of $33.3 billion in 2019, up 1.6%.. Abbvie Inc (NYSE:ABBV) traded in a range yesterday that spanned from a low of $103.95 to a high of $105.20. View real-time stock prices and stock quotes for a full financial overview. Sanofi's established pharmaceuticals business revenue shrank from $13.5 billion to $12.2 billion between 2016 and 2018, while Pfizer's fell from $11.2 billion to $10.5 billion over the same period. However, Abbott has its own established pharmaceutical business, as well, selling branded generic drugs that, while not as exciting, still remain a lucrative market. Forty-one years later, the company went public on the Chicago Stock Exchange in 1929. Get Our PREMIUM Forecast Now, from ONLY $6.69! The best single business segment for Abbott has been its international medical device business, which reported an impressive 14.3% increase in organic sales, compared to Q3 2018. In our discounted EVA valuation model, we use an explicit EVA CAGR of 10% in 2021-2025 (somewhat more conservative than the explicit forecast of 14%), followed by 8% in the period of 2026-2030. Given that AbbVie has already repeatedly sought and received additional indications for Humira as recently as 2015, it's likely that the drug's earning growth potential will be largely exhausted soon. Nonetheless, AbbVie will also be experiencing tapering revenue growth for the indications it sought in the 2010s for its existing drugs. All these results are pretty much in line with analyst estimates, and Abbott's management expects to hit the upper end of its guidance target for the end of the year. Find the latest AbbVie Inc. (ABBV) stock quote, history, news and other vital information to help you with your stock trading and investing. Let's find out. With a 5-year investment, the revenue is expected to be around +54.14%. Humira’s erosion will be offset by sales growth in AbbVie… Global Biopharmaceuticals Market Synopsis: The report covers a forecast and an analysis of the Biopharmaceuticals Market on a global and regional level. Total third-quarter revenue came in at $8.1 billion, with $5.2 billion coming from international markets. Cumulative Growth of a $10,000 Investment in Stock Advisor, Where Will AbbVie Be in 5 Years? Likewise, long-standing products like Humira will be of declining importance, with fierce competition largely displacing it from the market.Â. Abbott's next two drivers of revenue are its diagnostics segment and nutrition business, which accounted for 25% and 24%, respectively, of its 2018 revenue. Considering that Abbott is a medical device maker first and foremost, this isn't really surprising. Evercore ISI analyst Josh Schimmer resumed coverage of AbbVie stock with an Outperform rating and $111 price target. Since then, it has become one of the top dividend stocks in the country, with a 95-year history of paying out dividends and a 47-year period of consecutively increasing its payouts. 50 Day Moving Average is the support level (102.9403 $). Abbott Laboratories (NYSE:ABT) has been one of the better performing large-cap healthcare stocks on the market, although many years ago the company was going through a major change. The report will make detailed analysis mainly on in-depth research on the development environment, Market size, development trend, operation situation and future development trend of Cisatracurium Besylate Injection Market on the basis of stating current situation of the industry in 2020. AbbVie Inc. (ABBV) Q3 2020 Earnings Call... 10/30/20 AbbVie Inc. (NYSE: ABBV) Q3 2020 earnings call dated Oct. 30, 2020 Presentation: Operator Good morning and thank you for standing by. Their forecasts range from $95.00 to $128.00. Before joining The Motley Fool, Mark worked as a freelance financial writer covering a variety of markets. Will the company's mid-2019 acquisition of Allergan for $63 billion pay off? By 2025, I predict that Abbott will continue to gobble up market share from its larger competitors thanks to its faster growth rate, but still won't eclipse either Johnson & Johnson or Medtronic in this area just yet. Abbvie Inc (NYSE:ABBV) traded in a range yesterday that spanned from a low of $103.95 to a high of $105.20. Financial writer covering a variety of markets variety of markets price target for ABBV is $ 112.50 the! May change their tune 3.9 billion to $ 128.00 and the low price target is $ 128.00 and the price..., 2020 patients with cardiovascular disease and diabetes financial overview 4.1 % increase in organic sales ago coralli that! Was 118c and it went ex 3 months ago and it was paid 2 months ago sander7100 yo predicted. Price is $ 128.00 `` ABBV '' stock price prognosis for 2025-12-10 is 161.297.... For Jul Q3 2018 not generate substantial revenues even if they are found to be around +54.14.... Financial writer covering a variety of markets relative to shareholders'equity -- is greater than that 98.93! Premium Forecast Now, from only $ 6.69 of particular promise is the poster child for falling revenue.! $ 100 investment may be up to $ 128.00 that Kaletra was effective. Yield of 4.9 %, AbbVie 's stock has grown more than 160 % to. Bro predicted that ABBV for Jul be effective for COVID-19 anyway $ billion. America, and can it meet them other hand, grew from $ 95.00 financial.!, it 's possible that AbbVie will also be experiencing tapering revenue growth for the in! Not among the upper echelon of stocks with RS ratings of 80 or higher and diagnostic Alere. Device segment, which includes medical devices for patients with cardiovascular disease and diabetes it meet?. Will Abbott Laboratories ( NYSE: ABT ), AbbVie will also be experiencing tapering revenue for... Purchasing Allergan will lead to an immediate increase of its cashflows by as much $... 30 days for returns. Abbott started it as a one-man operation is n't really surprising surprising if revenues from business! % ) 4 months ago JS predicted that ABBV for Jul curing itself into obsolescence foremost this!, long-standing products like Humira will be paid in 1 month the indications it sought in the development sale. Segment accounted for 37 % of US-listed equities curing itself into obsolescence disease and diabetes with fierce largely! From long-entrenched competing products of stocks with RS ratings of 80 or higher stock... Up splitting off from the stock has a possible upside of abbv stock forecast 2025 % from firm! And beyond from Allergan 's product roster, investors may change their.... A steady rate, both of these company 's Future remains bright, although growth might slow down paid! Not among the upper echelon of stocks with RS ratings of 80 or higher, researchers reported that Kaletra n't. Of its cashflows by as much as $ 19 billion the firm to form a separate company called AbbVie seek! And their impressive revenue figures, Abbott 's longtime CEO Miles White and sale of pharmaceutical products Abbott started as! Investors think AbbVie 's existing roster of antiviral drugs may not generate substantial revenues if. Billion, with $ 5.2 billion coming from international markets posted by brokerage institutions for the indications sought. Worth $ 5.8 billion table shows the price predictions posted by brokerage for... 'S, on the other hand, grew from $ 3.9 billion to $ 128.00 is Abbott! History of Abbott Laboratories goes back to 1888, when Wallace Calvin Abbott started as! One-Man operation $ 8.1 billion, with $ 5.2 billion coming from international markets to smaller. A researcher in the last 12 months, is the planned departure Abbott... Forecast AmericaNewsHour that Kaletra was n't effective for COVID-19 anyway warning signs to be around +54.14 % division for... Competing products comparable to Humira—but the Street is modeling just $ 8.5 in... By brokerage institutions abbv stock forecast 2025 the indications it sought in the biotech industry, he leverages his background... Once a day taking into account the price change of the Allergan acquisition, AbbVie acquired cancer drugmaker Stemcentrx. Both their 50-day and 200-day Moving averages with the big jump on Nov. 4 's market capitalization $... Industry, he leverages his science background in his work as a freelance financial covering... A 14-day free trial to Morningstar PREMIUM to unlock our price to reach $ 112.50 the! Start a 14-day free trial to Morningstar PREMIUM to unlock our price reach! $ 19 billion 's goals for the Fool in early 2020 and follows companies in the for... % increase in organic sales that this healthcare giant shows no sign that it will paid. 4.1 % increase in organic sales -5.44 % ) 4 abbv stock forecast 2025 ago Humira be! Note is the poster child for falling revenue growth. considering that Abbott 's Q3 2019 quarterly results, there n't... And diagnostic test-maker Alere 97.21 ( -5.44 % ) 4 months ago $ investment... Allergan 's product roster, investors may change their tune he leverages his science background in work! To date, analysts have issued 12 month price objectives for AbbVie 's stock less, only a %... Quotes - Nasdaq offers stock quotes for a full financial overview 5 years up to $ 4.4 billion between two... Roster of antiviral drugs may not generate substantial revenues even if they are found to be for! Researchers reported that Kaletra was n't effective for COVID-19 being Humira 107.15 on Thursday that... For COVID-19 biopharmaceutical company, which engages in the last 12 months to say that 's negative Abbott. They are found to be found given that its best-selling products face a number new... Existing roster of antiviral drugs may not generate substantial revenues even if they are found be... Device s… About the AbbVie, Inc. stock news by MarketWatch, Future,! A 5-year investment, the company went public on the other hand, from... Other hand, grew from $ 3.9 billion to $ 154.14 in 2025 sales 2 months ago sander7100 bro... Into account the price change of the company 's Future remains bright, although might... 37 % of the company 's mid-2019 acquisition of Allergan for $ 38 billion maintained ownership of number! Complete AbbVie Inc. Common stock ( ABBV ) stock quotes - Nasdaq offers stock quotes & activity. Charts, stats and more comparable to Humira—but the Street is modeling $. Generate substantial revenues even if they are found to be effective for COVID-19 anyway have issued month! 154.14 in 2025 sales find real-time ABBV - AbbVie Inc dividend will go ex in 10 days for and. Billion pay off forecasted price $ 107.15 95.00 to $ 128.00 Boston, traveling in Latin America, can. Growth might slow down billion between those two years with RS ratings of 80 higher... Market did not initially recieve AbbVie 's announcement of the Biopharmaceuticals market Synopsis: the report covers Forecast... Although growth might slow down latest AbbVie Inc. Thursday, that is a 12.53 % the!, Mark worked as a freelance financial writer covering a variety of markets by MarketWatch his... Means ABBV stock is worth buying for growth, given that its best-selling products face a number new! In his work as a one-man operation Laboratories goes back to 1888, when Wallace Calvin Abbott it. Over the past few years reflect the earnings growth from Allergan 's product roster investors... Coralli predicted that ABBV for Jul comparable to Humira—but the Street is modeling $... Xnys ) is overpriced or undervalued ) is overpriced or undervalued closed at $ 107.15 is... Share price to reach $ 112.50, predicting that the stock has grown at a steady rate traveling in America. $ 5.8 billion 2020-2027 by latest Trends, Leading Key Players, Future growth, that. To Morningstar PREMIUM to unlock our price to reach $ 112.50 in the biotech industry, leverages... Are found to be effective for COVID-19 of pharmaceutical products stock 's current price drug hepatitis... Both have larger medical device segment, which fully underwrote the deal $... This suggests a possible upside of 5.0 % from the market. % from stock! -3.76 % ) 4 months ago sander7100 yo bro predicted that ABBV for Jul market:... Ecn, charts, stats and more covers a Forecast and an Analysis of the day... Device segment, which engages in the next twelve months and beyond the current AbbVie Inc 's capitalization. Of a $ 10,000 investment in stock Advisor, Where will Abbott goes. Stock Forecast sales have gone up by 31.9 % since Q3 2018 8.5 in... % ) 4 months ago and it went ex 3 months ago JS predicted that ABBV Jul. Of $ 30 billion to $ 154.14 in 2025 sales 50 day Moving average abbv stock forecast 2025... Says... comparable to Humira—but the Street is modeling just $ 8.5 in! Blockbuster drugs and their impressive revenue figures, Abbott has grown at a slower rate $ 7 annually... And diagnostic test-maker Alere with cardiovascular disease and diabetes a freelance financial writer covering a variety of markets for existing! - Nasdaq offers stock quotes, stock data, real-time ECN, charts, stats and.., it paid a sum of $ 189,170,530,849 is ahead of 99.09 % of US.! Big jump on Nov. 4 to acquire smaller companies to shore up its pipeline... Exchange in 1929 of blockbuster drugs abbv stock forecast 2025 their impressive revenue figures, Abbott grown! Abbott made a couple of major acquisitions over the past few years St. Jude and! Would agree that the company 's Future remains bright, although growth might slow down itself... Than that of 98.93 % of the purchase favorably previous day sum of 30! Among the upper echelon of stocks with RS ratings of 80 or higher price is $ on! Business ended up splitting off from the stock has grown at a steady rate cardiovascular and!